Pharmacia & Upjohn and Searle have signed a co-promotion agreement for Detrol, the treatment for overactive bladder. Beginning March 1, Searle will deploy approximately 475 sales reps to promote Detrol in the United States, raising the drug's combined sales force to approximately 1,800. Detrol is the market leader in the category, followed by Alza's Ditropan XL. Pharmacia & Upjohn also announced it will market Novo Nordisk's portfolio of hormone replacement therapy drugs in the United States, which include Activelle, Vagifem and Innofem.
COPYRIGHT 2000 Lebhar-Friedman, Inc.
COPYRIGHT 2000 Gale Group
Contact
Home
A
Hydrocodone